Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PBM Legislation And The Meaning Of ‘Meaningful’ Reform

Executive Summary

CEOs of J&J, Bristol Myers Squibb and Merck comment on the status of legislative policies reforming pharmacy benefit manager practices and the likelihood they will lower out-of-pocket costs for patients at a recent Senate hearing.

You may also be interested in...



Senate CEO Hearing On Drug Prices Could (Almost) Have Taken Place Five Years Ago

Discussion around the landmark developments in pricing reform established by the Inflation Reduction Act of 2022 were largely absent from the hearing involving Johnson & Johnson’s Joaquin Duato, Merck’s Robert Davis and Bristol Myers Squibb’s Chris Boerner.

Lilly’s Direct-to-Consumer GLP-1 Service Likely Doesn’t Threaten PBMs

Pharmacy benefit experts say that the move is sure to improve market access for Lilly’s weight loss drugs, but they also say that the impact of the new service on PBMs is likely to be minimal.

Medicare Price Negotiation Law Fixes Face ‘Big Problem,’ Former Trump Official Says

Health policy experts and biopharma supply chain stakeholders discuss prospects for legislation reforming the Inflation Reduction Act, pharmacy benefit manager practices, and the 340B program during a recent conference.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel